Biodexa Pharmaceuticals (NASDAQ:BDRX) Rating Increased to Hold at Wall Street Zen

Biodexa Pharmaceuticals (NASDAQ:BDRX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Biodexa Pharmaceuticals Trading Down 0.9%

Shares of BDRX stock traded down $0.02 during mid-day trading on Friday, hitting $2.15. 157,547 shares of the stock were exchanged, compared to its average volume of 469,344. Biodexa Pharmaceuticals has a 52-week low of $2.03 and a 52-week high of $92.00. The firm has a fifty day moving average of $3.69 and a 200 day moving average of $5.84.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.